早期肝癌患者血清AFU与AFP联合检测的临床价值

目的探讨联合检测血清AFU与AFP对诊断早期肝癌的临床价值。方法检测22例原发性肝癌、17例慢性乙肝性肝硬化以及50例健康体检者的血清AFU与AFP。结果AFU与AFP阳性率,肝癌组分别为68.2%与77.3%,而乙肝性肝硬化组分别为11.7%与5.7%,两组相比差异显著(P<0.001)。弥漫性肝癌与<3 cm的肝癌AFU的阳性率(分别为66.7%与75.0%)明显高于AFP的阳性率(分别为33.3%与50.0%,P<0.05)。结论AFU与AFP的联合检测能提高原发性肝癌的诊断率,特别是对早期肝癌的诊断。

Clinical Significance of Combined AFU and AFP Detection for Patients with Early Liver Cancer

Objective To study the clinical significance of combined alpha-L-fucosidase(AFU) and alpha-fetoprotein(AFP) detection for the diagnosis of early liver cancer.Methods Serum AFU and AFP were detected in 22 patients with primary liver cancer,17 with hepatocirrhosis originating from chronic hepatitis B and 50 healthy subjects.Results The positive rates of AFU and AFP were respectively 68.2% and 77.3% in liver cancer group,and 11.7% and 5.7% in hepatocirrhosis group. There were significant differences between the two groups(P<0.001).The AFU positive rates of diffused liver cancer(66.7%) and smal(<3cm) liver cancer(75.0%) were significantly higher than the AFP positive rates(33.3%,50.0%)(P<0.05).Conclusion Conclusion The diagnostic rate of primary liver cancer can be increased by combined AFU and AFP detection,especially in early cases.